DeCure for Type II hypersensitivity reaction disease
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for type II hypersensitivity reaction disease — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleType II hypersensitivity reaction disease maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for type ii hypersensitivity reaction disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
IKAROS family zinc finger 1 (IKZF1) — IKZF1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3-chloro-4-methylphenyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9Q2D · 2.94 Å · ligand 1-(3-chloro-4-methylphenyl)-3-({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}methyl)urea (85C). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts do not describe any treatment or drug repurposing for type II hypersensitivity reaction disease. They define type II reactions as cytotoxic, antibody-mediated hypersensitivity that can cause haemolysis and purpura, with penicillins, sulphonamides, cephalosporins, and rifampicin listed as typical triggers. No clinical trial, case series, or laboratory study testing a specific drug against type II reactions is reported. The 2010 review states that avoidance or prevention is not feasible and management consists of withdrawing the offending agent, supportive care, and symptomatic treatment. The 2012 review of antineoplastic hypersensitivity reactions mentions desensitisation protocols as an option for re-introducing the causative drug, but does not address type II reactions specifically.
No concrete numbers — survival, response rates, or sample sizes — appear in any abstract. The 2013 extract notes that fewer than 5% of cutaneous drug reactions have anti-drug antibodies, but this is a general observation, not a result from a therapeutic intervention. The 2009 abstract discusses nomenclature for drug hypersensitivity syndrome and the need for a surveillance programme, but offers no data on treatment outcomes. The 2018 chapter reviews classification and management without presenting original results.
What is missing is any clinical trial or preclinical study that tests a candidate drug for type II hypersensitivity disease. There is no evidence of patient stratification, no biomarker-driven selection, and no funding directed at repurposing for this indication. Without such data, no drug can be claimed to have efficacy, and no recommendation for treatment can be made.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Dermatology · 2009 · 61 citations
Drug Hypersensitivity Syndrome
AbstractSome types of hypersensitivity to drugs are defined either by the generic name of the drug or descriptive terms. They are sometimes assimilated to pseudolymphoma because the causative drugs are often the same, although the eruption lacks clinical and histopathological criteria of pseudolymphoma. It is then suggested to use 'idiosyncratic drug hypersensitivity syndrome' to define this type of drug reaction. As the skin and other organs may be involved, a generic name would help to determine a better definition and a surveillance program.
Allergic and hypersensitivity reactions in the intensive care unit
AbstractHypersensitivity reactions are defined as immunologically based adverse reactions to chemicals or medicinal agents. These reactions are common in the intensive care unit and can present as a simple, mildly symptomatic rash or as life-threatening anaphylactic reactions. Hypersensitivity reactions have traditionally been classified as types I to IV reactions based on the underlying immune mechanisms, although the clinical relevance of the classification is unclear, and new subtypes to this system have been recently proposed. Given the immunologic and often unpredictable nature of these reactions, avoidance or prevention is not a feasible option. Therefore, management has primarily consisted of withdrawal of potential offending agents, supportive therapy, symptomatic management, and, in some specific examples, targeted pharmacotherapy. This article outlines the background and types of hypersensitivity reactions and provides descriptions and management strategies when applicable to common types of hypersensitivity reactions encountered in the intensive care unit.
Farmacia Hospitalaria · 2012 · 12 citations · open access
Revisión de las reacciones de hipersensibilidad a antineoplásicos
AbstractOBJECTIVE: To review the characteristics and management of hypersensitivity reactions caused by antineoplastic agents. METHOD: We conducted a search in the Pubmed and EMBASE databases for the last 10 years. RESULTS: Almost all chemotherapeutic agents have the potential to cause hypersensitivity reactions, but some groups have been associated with increased risk, such as platinum compounds, taxanes, asparaginase, monoclonal antibodies and epipodophyllotoxins. The clinical manifestations of these reactions are variable and unpredictable, including symptoms affecting the skin and the pulmonary, cardiac and gastrointestinal systems. The mechanism associated with their development is not yet fully understood. Diagnosis is based on patients' signs and symptoms and skin testing. The management of patients who suffer a hypersensitivity reaction to a chemotherapeutic agent varies with the severity of the reaction, the need to continue treatment, and the availability of alternative therapies. CONCLUSIONS: Due to a progressive increase in the use of chemotherapeutic agents an increased incidence of hypersensitivity reactions is to be expected. Desensitisation protocols are a noteworthy alternative that make it possible to re-initiate patients' therapy with the causative agent of the hypersensitivity reaction. Their use should be assessed individually, weighing risks and benefits.
Alergologia Polska - Polish Journal of Allergology · 2023 · 3 citations · open access
Two types of hypersensitivity reaction including anaphylaxis and symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) after aminopenicillin administration in the same patient
AbstractAMA Rozłucka L, Gawlik R, Glück J. Two types of hypersensitivity reaction including anaphylaxis and symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) after aminopenicillin administration in the same patient. Alergologia Polska - Polish Journal of Allergology. 2023;10(4):315-318. doi:10.5114/pja.2023.132963. APA Rozłucka, L., Gawlik, R., & Glück, J. (2023). Two types of hypersensitivity reaction including anaphylaxis and symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) after aminopenicillin administration in the same patient. Alergologia Polska - Polish Journal of Allergology, 10(4), 315-318. https://doi.org/10.5114/pja.2023.132963 Chicago Rozłucka, Lesia, Radosław Gawlik, and Joanna Glück. 2023. "Two types of hypersensitivity reaction including anaphylaxis and symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) after aminopenicillin administration in the same patient". Alergologia Polska - Polish Journal of Allergology 10 (4): 315-318. doi:10.5114/pja.2023.132963. Harvard Rozłucka, L., Gawlik, R., and Glück, J. (2023). Two types of hypersensitivity reaction including anaphylaxis and symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) after aminopenicillin administration in the same patient. Alergologia Polska - Polish Journal of Allergology, 10(4), pp.315-318. https://doi.org/10.5114/pja.2023.132963 MLA Rozłucka, Lesia et al. "Two types of hypersensitivity reaction including anaphylaxis and symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) after aminopenicillin administration in the same patient." Alergologia Polska - Polish Journal of Allergology, vol. 10, no. 4, 2023, pp. 315-318. doi:10.5114/pja.2023.132963. Vancouver Rozłucka L, Gawlik R, Glück J. Two types of hypersensitivity reaction including anaphylaxis and symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) after aminopenicillin administration in the same patient. Alergologia Polska - Polish Journal of Allergology. 2023;10(4):315-318. doi:10.5114/pja.2023.132963.
AbstractExtract Overview Both immune- and non-immune-mediated drug reactions occur. Amongst immune-mediated drug reactions, the type I–IV classification is followed. Type I reactions These are IgE dependent reactions that lead to urticaria, angioedema, and anaphylaxis. Typical drugs that result in Type I reactions include therapeutic peptides. Type II reactions These are cytotoxic hypersensitivity reactions resulting in haemolysis and purpura. Typical drugs resulting in Type II reactions include penicillins, sulphonamides, cephalosporins, and rifampicin. Type III reactions These are immune complex mediated reactions leading to vasculitis, serum sickness and an urticarial rash. Drugs which are known to be associated with immune complex reactions include quinine, salicylates, and sulphonamides. Type IV reactions These reactions are not dose-dependent and usually begin 7–20 days after initiation of therapy, they are the commonest type of hypersensitivity drug reaction. Only a minority of cutaneous drug reactions, however, have a demonstrable link to IgE, with 〈5% having anti-drug antibodies. Drug-induced angioedema
Oxford University Press eBooks · 2018 · 0 citations
Hypersensitivity diseases
AbstractHypersensitivity reactions are aberrant immune responses that are provoked by innocuous extrinsic or self-antigens, are mediated by B-cells or T-cells, and may result in tissue or organ damage. Coombs and Gell classified hypersensitivity reactions into four types, based on the different immune responses: type I, or immediate hypersensitivity; type II, or antibody-mediated (humoral) cytotoxicity; type III, or immune-complex disease; and type IV, or delayed hypersensitivity. This chapter reviews the clinical features, diagnosis, and management of hypersensitivity reactions.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
